within Pharmacolibrary.Drugs.R_RespiratorySystem.R01A_DecongestantsAndOtherNasalPreparationsForTopicalUse.R01AX09_HyaluronicAcid;

model HyaluronicAcid
  extends Pharmacolibrary.Drugs.ATC.R.R01AX09;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>R01AX09</td></tr><td>route:</td><td>intranasal</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Hyaluronic acid is a naturally occurring glycosaminoglycan widely distributed throughout connective, epithelial, and neural tissues. As a drug, it is commonly used in the treatment of osteoarthritis (via intra-articular injection), as an adjunct in ophthalmic surgery, for wound healing, and as a moisturizer in topical formulations. Intranasal formulations (ATC code R01AX09) have been investigated for improving nasal mucosa hydration. Hyaluronic acid is generally regarded as safe and is used in a variety of medical devices and health products, but is not widely approved as a systemic drug.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for hyaluronic acid administered intranasally in adult subjects. No direct pharmacokinetic studies reporting plasma concentration data or modeling published for this administering route; parameters estimated from general literature on exogenous hyaluronic acid pharmacokinetics.</p><h4>References</h4><ol><li><p>Sabir, F, et al., &amp; Csóka, I (2021). Quality-by-Design-Based Development of n-Propyl-Gallate-Loaded Hyaluronic-Acid-Coated Liposomes for Intranasal Administration. <i>Molecules (Basel, Switzerland)</i> 26(5) –. DOI:<a href=&quot;https://doi.org/10.3390/molecules26051429&quot;>10.3390/molecules26051429</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33800788/&quot;>https://pubmed.ncbi.nlm.nih.gov/33800788</a></p></li><li><p>Serri, C, et al., &amp; Gavini, E (2025). Hyaluronic Acid-Based Hybrid Nanoparticles as Promising Carriers for the Intranasal Administration of Dimethyl Fumarate. <i>International journal of nanomedicine</i> 20 71–89. DOI:<a href=&quot;https://doi.org/10.2147/IJN.S481917&quot;>10.2147/IJN.S481917</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/39802381/&quot;>https://pubmed.ncbi.nlm.nih.gov/39802381</a></p></li><li><p>Pandey, A, et al., &amp; Sawant, K (2019). Hyaluronic acid tethered pH-responsive alloy-drug nanoconjugates for multimodal therapy of glioblastoma: An intranasal route approach. <i>Materials science &amp; engineering. C, Materials for biological applications</i> 98 419–436. DOI:<a href=&quot;https://doi.org/10.1016/j.msec.2018.12.139&quot;>10.1016/j.msec.2018.12.139</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/30813043/&quot;>https://pubmed.ncbi.nlm.nih.gov/30813043</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end HyaluronicAcid;
